Zepbound® is a prescription medicine that contains tirzepatide. It’s used for chronic weight management in adults with obesity, or with overweight and at least one weight-related medical condition, alongside a reduced-calorie diet and increased physical activity.
Get startedZepbound® contains tirzepatide, a prescription medicine that activates two hormone pathways: GIP and GLP-1. By engaging these receptors, tirzepatide helps regulate appetite and metabolism. Many people experience reduced hunger, improved fullness after meals, and better control over cravings - supporting meaningful, sustained weight reduction when combined with lifestyle changes.
Zepbound® is injected subcutaneously (under the skin) once weekly, on the same day each week, at any time of day, with or without food.
Common injection sites include:
Rotate injection sites each week and avoid injecting into skin that is tender, bruised, red, or hard. Use Zepbound® exactly as prescribed and keep regular follow-ups—your clinician may adjust your dose over time to support tolerability and results.
Common side effects may include:
More serious side effects are possible. This medication is not appropriate for individuals with certain medical conditions. A full medical evaluation is required prior to starting treatment.
Zepbound® is a prescription medicine containing tirzepatide used for long-term weight management in eligible adults, together with nutrition and activity changes. It is designed for consistent, ongoing use under clinician guidance—because sustainable weight reduction is typically a long-term plan, not a short-term fix.
Images are for illustrative purposes only. Individual results may vary. Compounded medications are not FDA-approved.
Tirzepatide activates two hormone pathways—GIP and GLP-1. By engaging both receptors, it can support weight reduction by helping to:
This dual-action mechanism is designed to support meaningful and sustained weight reduction when paired with lifestyle changes.
Images are for illustrative purposes only. Individual results may vary. Compounded medications are not FDA-approved.
Zepbound® is injected once per week, on the same day each week, with or without food. Injection sites include the abdomen, thigh, or upper arm. Consistency matters—staying on schedule and rotating sites can help support comfort and routine.
Regular clinician follow-up is important to monitor progress, manage side effects, and adjust dosage if needed for safe, effective use.
Images are for illustrative purposes only. Individual results may vary. Compounded medications are not FDA-approved.
Clinical studies of GLP-1 medications have shown weight reduction in some patients when used under medical supervision. Individual results vary.
* For illustrative estimate only.
** Estimates reflect ranges reported in clinical studies of GLP-1 medications. Individual results vary. Treatment, dosing, and outcomes are determined by a licensed clinician following clinical evaluation. Compounded medications are not FDA-approved.
Zepbound® is a brand-name prescription injection containing tirzepatide. It’s FDA‑approved for chronic weight management in adults with obesity or overweight with certain weight‑related conditions, as part of a reduced‑calorie diet and increased physical activity.
Tirzepatide activates two hormone pathways (GIP and GLP‑1) involved in appetite regulation and metabolic control. This can help reduce hunger, increase fullness, and support lower calorie intake over time.
Eligibility is determined by a licensed clinician based on factors such as BMI, weight‑related health conditions, medical history, and medication safety. It may not be appropriate for people with certain thyroid conditions, a history of pancreatitis, or those who are pregnant or planning pregnancy.
Some people notice appetite changes in the first few weeks. Weight changes typically become more noticeable over 8–12 weeks and may continue as the dose is adjusted for tolerability and results.
Yes. Clinicians usually start at a lower dose and increase gradually to reduce side effects. Your dose and titration schedule are individualized based on how you respond and tolerate the medication.
The most common side effects are gastrointestinal—nausea, diarrhea, constipation, vomiting, stomach discomfort, and reduced appetite—especially during dose increases. Many people find symptoms improve as the body adapts.
Seek urgent medical care for severe or persistent abdominal pain, signs of an allergic reaction, repeated vomiting with dehydration, or symptoms of very low blood sugar (especially if you take insulin or sulfonylureas). Always contact your clinician if anything feels concerning.
Zepbound is taken as a once‑weekly subcutaneous injection. Your clinician will provide instructions for injection technique, site rotation, storage, and what to do if you travel or change your dosing day.
If you miss an injection, follow your clinician’s instructions and the medication guide. In general, take it as soon as you remember if it’s close to your usual schedule, or skip and resume your regular dosing day—avoid taking two doses close together.
Zepbound is not typically used together with other GLP‑1 medications. Your clinician will review your current meds and choose one appropriate option rather than combining similar agents.
Medication works best alongside sustainable nutrition and activity habits. Your clinician can help set realistic goals and create a plan that supports long‑term results and maintenance.
Cost and coverage vary by insurance plan and eligibility. Many plans require prior authorization, and out‑of‑pocket pricing can differ by pharmacy. We’ll help you review coverage options and discuss alternatives if needed.
A GLP-1 plateau can feel discouraging, but it’s often a normal checkpoint, not a failure.
As weight decreases, your body adapts. Energy needs can change, and routines that worked early may become less effective. Plateaus can also reflect inconsistent nutrition (especially protein), reduced movement, stress, or sleep disruption.
Treat a plateau like feedback. It’s telling you what needs refinement: habits, support, expectations, or clinical oversight.
Tirzepatide-based therapy may be used in clinician-guided programs for chronic weight management in appropriate patients, alongside nutrition and physical activity changes.
A clinician must screen for contraindications and risk factors. Patients should disclose current medications, past adverse reactions, pregnancy status, and relevant family history.
Patients must know what symptoms require immediate medical attention (severe or persistent vomiting, dehydration signs, severe abdominal pain, allergic reactions), and how to reach your clinical support.
If compounded: state clearly that compounded drugs are not FDA-approved and are not evaluated by the FDA for safety, effectiveness, or quality prior to marketing.
If medication is provided in a vial, dosing errors are a known risk when patients measure doses themselves. Provide a step-by-step injection basics guide, measurement safety reminders, and “contact your clinician if unsure” instructions.
Wondering whether you qualify for a GLP-1 medication? The goal of eligibility screening is to confirm that treatment is medically appropriate, safe, and sustainable for your health profile.
While only a licensed clinician can determine eligibility, most evaluations consider:
Many programs use BMI plus clinical context. Some individuals qualify based on weight thresholds alone; others qualify based on weight plus weight-related conditions. Your clinician should also consider weight history and prior lifestyle interventions.
Your current prescriptions and supplements matter, especially if you take medications that affect blood sugar or appetite.
GLP-1 therapy is most effective with nutrition, movement, and follow-up. A responsible provider sets expectations about timelines, side effects, and what happens if you stop treatment.
Not everyone is a candidate. A proper review screens for conditions where GLP-1 therapy may be inappropriate or require special caution, along with pregnancy status and relevant family history.
Have your height, weight, medication list, and any recent labs available. Write down your goals and constraints (budget, travel schedule, injection comfort).
If you’re told you do not qualify, your next step should still be constructive: alternatives, lifestyle support, or in-person medical referral when needed. Eligibility is not about “selling a product.” It’s about matching the right care to the right patient.
.webp)
